FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:781-789 September 12, 2002 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Walsh, P. C. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Radical prostatectomy is widely used in the treatment of early prostate cancer. The possible survival benefit of this treatment, however, is unclear. We conducted a randomized trial to address this question.

Methods From October 1989 through February 1999, 695 men with newly diagnosed prostate cancer in International Union against Cancer clinical stage T1b, T1c, or T2 were randomly assigned to watchful waiting or radical prostatectomy. We achieved complete follow-up through the year 2000 with blinded evaluation of causes of death. The primary end point was death due to prostate cancer, and the secondary end points were overall mortality, metastasis-free survival, and local progression.

Results During a median of 6.2 years of follow-up, 62 men in the watchful-waiting group and 53 in the radical-prostatectomy group died (P=0.31). Death due to prostate cancer occurred in 31 of 348 of those assigned to watchful waiting (8.9 percent) and in 16 of 347 of those assigned to radical prostatectomy (4.6 percent) (relative hazard, 0.50; 95 percent confidence interval, 0.27 to 0.91; P=0.02). Death due to other causes occurred in 31 of 348 men in the watchful-waiting group (8.9 percent) and in 37 of 347 men in the radical-prostatectomy group (10.6 percent). The men assigned to surgery had a lower relative risk of distant metastases than the men assigned to watchful waiting (relative hazard, 0.63; 95 percent confidence interval, 0.41 to 0.96).

Conclusions In this randomized trial, radical prostatectomy significantly reduced disease-specific mortality, but there was no significant difference between surgery and watchful waiting in terms of overall survival.

Source Information

From the Regional Oncologic Center (L.H.) and the Department of Urology (A.B.-A., M.H., B.J.N.), University Hospital, Uppsala, Sweden; the Center for Assessment of Medical Technology (F.H., J.-E.J.) and the Department of Urology (S.-O.A., J.-E.J.), Örebro University Hospital, Örebro, Sweden; the Department of Urology, Helsinki University Hospital, Helsinki, Finland (J.O.S.); the Department of Urology, Borås Hospital, Borås, Sweden (P.F.); the Department of Urology, University Hospital, Linköping, Sweden (A.S.); the Department of Pathology, University Hospital, Tromsö, Norway (C.B.); the Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland (S.N.); the Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden (J.P., H.-O.A.); and the Department of Epidemiology and the Harvard Center for Cancer Prevention, Harvard School of Public Health, Boston (H.-O.A.).

Drs. Johansson and Norlén contributed equally to the article.

Address reprint requests to Dr. Bill-Axelson at the Department of Urology, University Hospital, SE-751 85 Uppsala, Sweden, or at anna.bill-axelson{at}urologi.uas.lul.se.

Full Text of this Article

This article has been cited by other articles:

• Bill-Axelson, A., Holmberg, L., Filen, F., Ruutu, M., Garmo, H., Busch, C., Nordling, S., Haggman, M., Andersson, S.-O., Bratell, S., Spangberg, A., Palmgren, J., Adami, H.-O., Johansson, J.-E., for the Scandinavian Prostate Cancer Group Study N, (2008). Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. JNCI J Natl Cancer Inst 100: 1144-1154 [Abstract] [Full Text]  
• Mucci, L. A., Pawitan, Y., Demichelis, F., Fall, K., Stark, J. R., Adami, H.-O., Andersson, S.-O., Andren, O., Eisenstein, A., Holmberg, L., Huang, W., Kantoff, P. W., Kim, R., Perner, S., Stampfer, M. J., Johansson, J.-E., Rubin, M. A. (2008). Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol. Biomarkers Prev. 17: 1682-1688 [Abstract] [Full Text]  
• Lewis, H. D., Winter, A., Murphy, T. F., Tripathi, S., Pandey, V. N., Barton, B. E. (2008). STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends. Molecular Cancer Therapeutics 7: 1543-1550 [Abstract] [Full Text]  
• Fall, K., Garmo, H., Andren, O., Bill-Axelson, A., Adolfsson, J., Adami, H.-O., Johansson, J.-E., Holmberg, L. (2007). Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer. JNCI J Natl Cancer Inst 99: 526-532 [Abstract] [Full Text]  
• Bailey, D. E. Jr, Wallace, M. (2007). Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer?. American Journal of Men's Health 1: 18-28 [Abstract]  
• Ramsey, S. D. (2007). How Should We Pay the Piper When He's Calling the Tune? On the Long-Term Affordability of Cancer Care in the United States. JCO 25: 175-179 [Full Text]  
• Wong, Y.-N., Mitra, N., Hudes, G., Localio, R., Schwartz, J. S., Wan, F., Montagnet, C., Armstrong, K. (2006). Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men. JAMA 296: 2683-2693 [Abstract] [Full Text]  
• Otto, S. J., Schroder, F. H., de Koning, H. J. (2006). Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial. JCO 24: 4184-4189 [Abstract] [Full Text]  
• Reske, S. N., Blumstein, N. M., Neumaier, B., Gottfried, H.-W., Finsterbusch, F., Kocot, D., Moller, P., Glatting, G., Perner, S. (2006). Imaging Prostate Cancer with 11C-Choline PET/CT. JNM 47: 1249-1254 [Abstract] [Full Text]  
• Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., Papadimitrakopoulou, V. A., Lotan, R., Aggarwal, B. B., Bresalier, R. S., Kim, J., Arun, B., Lu, K. H., Thomas, M. E., Rhodes, H. E., Brewer, M. A., Follen, M., Shin, D. M., Parnes, H. L., Siegfried, J. M., Evans, A. A., Blot, W. J., Chow, W.-H., Blount, P. L., Maley, C. C., Wang, K. K., Lam, S., Lee, J. J., Dubinett, S. M., Engstrom, P. F., Meyskens, F. L. Jr., O'Shaughnessy, J., Hawk, E. T., Levin, B., Nelson, W. G., Hong, W. K., for the AACR Task Force on Cancer Prevention, (2006). Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward. Clin. Cancer Res. 12: 3661-3697 [Abstract] [Full Text]  
• Gwede, C. K., McDermott, R. J. (2006). Prostate Cancer Screening Decision Making Under Controversy: Implications for Health Promotion Practice. Health Promot Pract 7: 134-146 [Abstract]  
• Hricak, H (2005). MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br. J. Radiol. 78: S103-S111 [Abstract] [Full Text]  
• Sox, H. C., Mulrow, C. (2005). An Editorial Update: Should Benefits of Radical Prostatectomy Affect the Decision To Screen for Early Prostate Cancer?. ANN INTERN MED 143: 232-233 [Full Text]  
• Talcott, J. A. (2005). Employment After Therapy for Localized Prostate Cancer: Widening the Perspective. JNCI J Natl Cancer Inst 97: 948-949 [Full Text]  
• Alibhai, S. M.H., Gogov, S. (2005). In patients with early prostate cancer, is surgery better than watchful waiting?. CMAJ 172: 1682-1682 [Full Text]  
• Rubin, M. A., Bismar, T. A., Andren, O., Mucci, L., Kim, R., Shen, R., Ghosh, D., Wei, J. T., Chinnaiyan, A. M., Adami, H.-O., Kantoff, P. W., Johansson, J.-E. (2005). Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death. Cancer Epidemiol. Biomarkers Prev. 14: 1424-1432 [Abstract] [Full Text]  
• Bill-Axelson, A., Holmberg, L., Ruutu, M., Haggman, M., Andersson, S.-O., Bratell, S., Spangberg, A., Busch, C., Nordling, S., Garmo, H., Palmgren, J., Adami, H.-O., Norlen, B. J., Johansson, J.-E., the Scandinavian Prostate Cancer Group Study No. 4, (2005). Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer. NEJM 352: 1977-1984 [Abstract] [Full Text]  
• Albertsen, P. C., Hanley, J. A., Fine, J. (2005). 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 293: 2095-2101 [Abstract] [Full Text]  
• Labrie, F., Belanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005). Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer. Endocr. Rev. 26: 361-379 [Abstract] [Full Text]  
• Dotan, Z. A, Bianco, F. J. Jr, Rabbani, F., Eastham, J. A., Fearn, P., Scher, H. I., Kelly, K. W., Chen, H.-N., Schoder, H., Hricak, H., Scardino, P. T., Kattan, M. W. (2005). Pattern of Prostate-Specific Antigen (PSA) Failure Dictates the Probability of a Positive Bone Scan in Patients With an Increasing PSA After Radical Prostatectomy. JCO 23: 1962-1968 [Abstract] [Full Text]  
• McNutt, R. A. (2004). Shared Medical Decision Making: Problems, Process, Progress. JAMA 292: 2516-2518 [Full Text]  
• (2004). Management of localised prostate cancer. DTB 42: 81-85 [Abstract] [Full Text]  
• Johansson, J.-E., Andren, O., Andersson, S.-O., Magnusson, A., Dickman, P. W., Holmberg, L., Adami, H.-O. (2004). Natural History of Early Localized Prostate Cancer--Reply. JAMA 292: 1549-1550 [Full Text]  
• Liu, P. Y., Swerdloff, R. S., Veldhuis, J. D. (2004). The Rationale, Efficacy and Safety of Androgen Therapy in Older Men: Future Research and Current Practice Recommendations. J. Clin. Endocrinol. Metab. 89: 4789-4796 [Abstract] [Full Text]  
• McNaughton-Collins, M., Walker-Corkery, E., Barry, M. J. (2004). Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000. J Natl Cancer Inst Monogr 2004: 78-101 [Abstract] [Full Text]  
• Claus, F. G., Hricak, H., Hattery, R. R. (2004). Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy. RadioGraphics 24: S167-S180 [Abstract] [Full Text]  
• Bermejo, C., Kristal, A. R., Zeliadt, S. B., Ramsey, S., Thompson, I. M. (2004). Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy. JNCI J Natl Cancer Inst 96: 1348-1349 [Full Text]  
• Potosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., Penson, D. F., Harlan, L. C. (2004). Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study. JNCI J Natl Cancer Inst 96: 1358-1367 [Abstract] [Full Text]  
• D'Amico, A. V., Chen, M.-H., Roehl, K. A., Catalona, W. J. (2004). Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy. NEJM 351: 125-135 [Abstract] [Full Text]  
• Johansson, J.-E., Andren, O., Andersson, S.-O., Dickman, P. W., Holmberg, L., Magnuson, A., Adami, H.-O. (2004). Natural History of Early, Localized Prostate Cancer. JAMA 291: 2713-2719 [Abstract] [Full Text]  
• Neugut, A. I., Grann, V. R. (2004). Waiting Time in Prostate Cancer. JAMA 291: 2757-2758 [Full Text]  
• Cooperberg, M. R., Lubeck, D. P., Meng, M. V., Mehta, S. S., Carroll, P. R. (2004). The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management. JCO 22: 2141-2149 [Abstract] [Full Text]  
• Fagerlin, A., Rovner, D., Stableford, S., Jentoft, C., Wei, J. T., Holmes-Rovner, M. (2004). Patient Education Materials about the Treatment of Early-Stage Prostate Cancer: A Critical Review. ANN INTERN MED 140: 721-728 [Abstract] [Full Text]  
• Tsujimoto, Y., Tomita, Y., Hoshida, Y., Kono, T., Oka, T., Yamamoto, S., Nonomura, N., Okuyama, A., Aozasa, K. (2004). Elevated Expression of Valosin-Containing Protein (p97) Is Associated with Poor Prognosis of Prostate Cancer. Clin. Cancer Res. 10: 3007-3012 [Abstract] [Full Text]  
• Stephenson, A. J., Shariat, S. F., Zelefsky, M. J., Kattan, M. W., Butler, E. B., Teh, B. S., Klein, E. A., Kupelian, P. A., Roehrborn, C. G., Pistenmaa, D. A., Pacholke, H. D., Liauw, S. L., Katz, M. S., Leibel, S. A., Scardino, P. T., Slawin, K. M. (2004). Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. JAMA 291: 1325-1332 [Abstract] [Full Text]  
• Yegnasubramanian, S., Kowalski, J., Gonzalgo, M. L., Zahurak, M., Piantadosi, S., Walsh, P. C., Bova, G. S., De Marzo, A. M., Isaacs, W. B., Nelson, W. G. (2004). Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer. Cancer Res. 64: 1975-1986 [Abstract] [Full Text]  
• Kao, J, Turian, J, Meyers, A, Hamilton, R J, Smith, B, Vijayakumar, S, Jani, A B (2004). Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br. J. Radiol. 77: 129-136 [Abstract] [Full Text]  
• Godley, P. A., Schenck, A. P., Amamoo, M. A., Schoenbach, V. J., Peacock, S., Manning, M., Symons, M., Talcott, J. A. (2003). Racial Differences in Mortality Among Medicare Recipients After Treatment for Localized Prostate Cancer. JNCI J Natl Cancer Inst 95: 1702-1710 [Abstract] [Full Text]  
• Giarelli, E., McCorkle, R., Monturo, C. (2003). Caring for a Spouse after Prostate Surgery: The Preparedness Needs of Wives. Journal of Family Nursing 9: 453-485 [Abstract]  
• Clark, J. A., Inui, T. S., Silliman, R. A., Bokhour, B. G., Krasnow, S. H., Robinson, R. A., Spaulding, M., Talcott, J. A. (2003). Patients' Perceptions of Quality of Life After Treatment for Early Prostate Cancer. JCO 21: 3777-3784 [Abstract] [Full Text]  
• Bott, S R J, Birtle, A J, Taylor, C J, Kirby, R S (2003). Prostate cancer management: (1) an update on localised disease. Postgrad. Med. J. 79: 575-580 [Abstract] [Full Text]  
• Liu, G., Wilding, G., Staab, M. J., Horvath, D., Miller, K., Dresen, A., Alberti, D., Arzoomanian, R., Chappell, R., Bailey, H. H. (2003). Phase II Study of 1{alpha}-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer. Clin. Cancer Res. 9: 4077-4083 [Abstract] [Full Text]  
• Landefeld, C S. (2003). Improving Health Care for Older Persons. ANN INTERN MED 139: 421-424 [Abstract] [Full Text]  
• Alibhai, S. M.H., Naglie, G., Nam, R., Trachtenberg, J., Krahn, M. D. (2003). Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?. JCO 21: 3318-3327 [Abstract] [Full Text]  
• Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., Kuntz, K. M. (2003). Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen. NEJM 349: 335-342 [Abstract] [Full Text]  
• Albertsen, P. C. (2003). The Prostate Cancer Conundrum. JNCI J Natl Cancer Inst 95: 930-931 [Full Text]  
• Sorum, P. C., Shim, J., Chasseigne, G., Bonnin-Scaon, S., Cogneau, J., Mullet, E. (2003). Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients?. Med Decis Making 23: 301-313 [Abstract]  
• Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., Weissleder, R. (2003). Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer. NEJM 348: 2491-2499 [Abstract] [Full Text]  
• Eastham, J. A., Riedel, E., Scardino, P. T., Shike, M., Fleisher, M., Schatzkin, A., Lanza, E., Latkany, L., Begg, C. B. (2003). Variation of Serum Prostate-Specific Antigen Levels: An Evaluation of Year-to-Year Fluctuations. JAMA 289: 2695-2700 [Abstract] [Full Text]  
• Wilt, T. J (2003). Radical prostatectomy reduced death from prostate cancer but not all cause mortality. Evid. Based Med. 8: 41-41 [Full Text]  
• Ford, L. G., Minasian, L. M., McCaskill-Stevens, W., Pisano, E. D., Sullivan, D., Smith, R. A. (2003). Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients. CA Cancer J Clin 53: 82-101 [Abstract] [Full Text]  
• Curtis, S., Lynch, R. M (2003). Screening for aortic aneurysm. BMJ 326: 284-284 [Full Text]  
• Blanker, M. H., Bierma-Zeinstra, S. M.A., Schouten, B. W.V., Coen, J. J., Zietman, A. L., Shipley, W. U., Gambacorti-Passerini, C. B., Sala, E. A., Sonpavde, G., Stern, S. D., Bill-Axelson, A., Holmberg, L. (2003). Prostatectomy or Watchful Waiting in Prostate Cancer. NEJM 348: 170-171 [Full Text]  
• Jewett, M. A.S., Fleshner, N., Klotz, L. H., Nam, R. K., Trachtenberg, J. (2003). Radical prostatectomy as treatment for prostate cancer. CMAJ 168: 44-45 [Full Text]  
• Kakehi, Y. (2003). Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era. Jpn J Clin Oncol 33: 1-5 [Abstract] [Full Text]  
• WAXMAN, J., MAZHAR, D. (2003). How are we looking after prostate cancer?. QJM 96: 75-79 [Full Text]  
• Smith, R. A., Cokkinides, V., Eyre, H. J. (2003). American Cancer Society Guidelines for the Early Detection of Cancer, 2003. CA Cancer J Clin 53: 27-43 [Abstract] [Full Text]  
• Harris, R., Lohr, K. N. (2002). Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 137: 917-929 [Abstract] [Full Text]  
• Chabner, B. A., Kaufman, D. (2002). Pity the Poor Consumer. The Oncologist 7: 475-476 [Full Text]  
• Gottlieb, S. (2002). Watchful waiting as good as surgery for prostate cancer. BMJ 325: 613-613 [Full Text]  
• Lenzer, J. (2002). Press: The operation was a success (but the patients died). BMJ 325: 664-664 [Full Text]  
• (2002). Prostatectomy vs. Watchful Waiting in Early Prostate Cancer. JWatch General 2002: 1-1 [Full Text]  
• Steineck, G., Helgesen, F., Adolfsson, J., Dickman, P. W., Johansson, J.-E., Norlen, B. J., Holmberg, L., the Scandinavian Prostatic Cancer Group Study Numb, (2002). Quality of Life after Radical Prostatectomy or Watchful Waiting. NEJM 347: 790-796 [Abstract] [Full Text]  
• Walsh, P. C. (2002). Surgery and the Reduction of Mortality from Prostate Cancer. NEJM 347: 839-840 [Full Text]